Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK announce an innovative drug discovery consortium with industry, supported by the Wellcome Trust.

The Psychiatry Consortium will focus on the identification and validation of novel drug targets for psychiatric diseases, including the psychiatric symptoms associated with dementia.

Anchored to patients by the leading medical charities and managed by Medicines Discovery Catapult, the consortium will foster new and truly needed innovative research approaches and revitalise psychiatric drug discovery. Collectively, the strategic partners aim to provide approximately £3 million in research funding over a period of 3 years with the aim of delivering up to 10 high-value drug discovery projects.

The Wellcome Trust will support the consortium to promote reach and engagement within the academic community. Major industry players engaged as inaugural members of the consortium include: Biogen, Boehringer Ingelheim, Johnson & Johnson Innovation, Lundbeck, MSD (trade name of Merck & Co., Inc., Kenilworth, NJ, USA) and Takeda.

The consortium will enable collaboration between academia, industry, charities and government funded organisations to develop and deliver a portfolio of innovative collaborative projects to accelerate psychiatric disease research and ultimately provide better treatment options to patients.

The first call for proposals to the consortium will be announced after the summer, and more information will be made available over the coming weeks on the Consortium website.

Back to e-newsletter